US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug

Namodenoson Drug Development - Namodenoson, a small orally bioavailable drug, has been granted a US patent for its use as an anti-obesity drug, valid until 2042 [1][2] - The drug is currently being developed for the treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH), advanced liver cancer, and pancreatic cancer [1][6] - In clinical studies, Namodenoson demonstrated a favorable safety profile and a 2.3% weight loss in patients after 3 months, with increased serum adiponectin levels [1][3] Anti-Obesity Mechanism and Market Potential - Namodenoson reduces fat levels by increasing adiponectin, a hormone that regulates fat production, and has shown weight loss in animal models of obesity [3] - The global obesity treatment industry is projected to reach $60.5 billion by 2030, with a compound annual growth rate of 22.3% from 2025 to 2030 [5] Can-Fite BioPharma Overview - Can-Fite BioPharma is an advanced clinical-stage drug development company focusing on cancer, liver, and inflammatory diseases [8] - The company's platform technology targets multi-billion dollar markets, with Namodenoson being a key drug candidate in Phase III trials for liver cancer and Phase IIb trials for MASH [6][8] - Namodenoson has received Orphan Drug Designation in the US and Europe and Fast Track Designation for hepatocellular carcinoma (HCC) treatment [8]